Holen Sie sich die Stockscreener-App
3.02
1.63%
-0.05
Schlusskurs vom Vortag:
$3.07
Offen:
$3
24-Stunden-Volumen:
11,210
Relative Volume:
0.24
Marktkapitalisierung:
$96.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.74M
KGV:
-0.1608
EPS:
-18.7859
Netto-Cashflow:
$-15.75M
1W Leistung:
-4.73%
1M Leistung:
+0.33%
6M Leistung:
-37.73%
1J Leistung:
-57.94%
1-Tages-Spanne:
$2.94
$3.02
1-Wochen-Bereich:
$2.92
$3.25
52-Wochen-Spanne:
$2.60
$14.69
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Firmenname
Dogwood Therapeutics Inc
Sektor
Branche
Telefon
(866) 620-8655
Adresse
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
3.02 | 98.49M | 0 | -24.74M | -15.75M | -18.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
DWTX: Financing Secures Funding Through Phase 2b Data Readout - Smartkarma
Institution Moves: Will Dogwood Therapeutics Inc. benefit from geopolitical trends2025 Macro Impact & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - markets.businessinsider.com
Cancer pain drug Halneuron shows early promise as major trial hits halfway - Stock Titan
What is Dogwood Therapeutics Inc.’s book value per share2025 Earnings Surprises & Low Risk Profit Maximizing Plans - mfd.ru
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Analysis Recap: Is AAON Inc impacted by rising ratesQuarterly Profit Review & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Price Action: What is the PEG ratio of Dogwood Therapeutics IncDip Buying & Stepwise Trade Signal Guides - baoquankhu1.vn
Dogwood Therapeutics outlines 2026 plans for pain pipeline - The Globe and Mail
Dogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% Surge - MSN
Dogwood Therapeutics, Inc. Provides Corporate Update - TradingView — Track All Markets
Trend Report: Does ATUS stock have upside surprise potentialJuly 2025 Action & Verified Swing Trading Watchlists - baoquankhu1.vn
Retail Trends: Is Dogwood Therapeutics Inc stock showing strong momentumMarket Activity Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Support Test: Is Dogwood Therapeutics Inc stock showing strong momentumJuly 2025 Closing Moves & Advanced Technical Signal Analysis - baoquankhu1.vn
Dogwood Therapeutics Raises Capital via Registered Direct Financing - The Globe and Mail
Geopolitics Watch: Will Dogwood Therapeutics Inc stock maintain momentum in 2025Bull Run & Free Daily Entry Point Trade Alerts - Bộ Nội Vụ
Dogwood Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Bull Run: Can Dogwood Therapeutics Inc stock sustain revenue growthJuly 2025 Breakouts & High Accuracy Trade Alerts - Bộ Nội Vụ
Risk Off: Whats Dogwood Therapeutics Incs historical return2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - TradingView — Track All Markets
New funding backs a non-opioid drug for chemotherapy nerve pain - Stock Titan
Will Dogwood Therapeutics Inc. stock continue upward momentum2025 Year in Review & Stepwise Entry and Exit Trade Signals - ulpravda.ru
Will Dogwood Therapeutics Inc. stock recover faster than market2025 Major Catalysts & Capital Efficiency Focused Ideas - ulpravda.ru
Will Dogwood Therapeutics Inc. stock split again soonJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - Улправда
Why Dogwood Therapeutics Inc. stock is trending among retail tradersInsider Selling & Weekly Setup with High ROI Potential - ulpravda.ru
Can Dogwood Therapeutics Inc. stock hit record highs againJuly 2025 WrapUp & Fast Entry High Yield Tips - Улправда
What technical charts say about Dogwood Therapeutics Inc. stock2025 Performance Recap & Daily Entry Point Trade Alerts - Улправда
Momentum Shift: Will Dogwood Therapeutics Inc. stock recover faster than market2025 Major Catalysts & Capital Efficiency Focused Ideas - Улправда
How sustainable is Dogwood Therapeutics Inc. stock dividend payout2025 Earnings Surprises & Accurate Technical Buy Alerts - Улправда
Why Dogwood Therapeutics Inc. stock remains a top recommendationEx-Dividend Date Alerts & Rapid Wealth Building Tips - ulpravda.ru
Can Dogwood Therapeutics Inc. stock rebound after recent weaknessEarnings Season Recap & Add These Before Everyone Else Does - bollywoodhelpline.com
DWTX: Positive Interim Results for Halneuron Phase 2b Trial in CINP Raising Valuation to 15 - Research Tree
Aug Chart Watch: What hedge fund activity signals for Dogwood Therapeutics Inc stockProfit Target & Stock Portfolio Risk Management - moha.gov.vn
DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15 - Zacks Small Cap Research
Trading Recap: Can Dogwood Therapeutics Inc stock hit record highs againJuly 2025 Final Week & Risk Managed Investment Entry Signals - moha.gov.vn
What date does Dogwood Therapeutics, Inc's (DWTX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Aug Big Picture: Will Dogwood Therapeutics Inc stock continue upward momentumTrade Risk Assessment & Safe Entry Point Alerts - moha.gov.vn
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc? - Benzinga
Halneuron Shows Pain Relief Separation In Interim Phase 2b Trial - Nasdaq
CKLIFE SCIENCES: Positive Results Obtained from Interim Analysis of Halneuron Phase 2b Study - AASTOCKS.com
DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence - Stocktwits
Dogwood Therapeutics stock plummets after Phase 2b interim results By Investing.com - Investing.com South Africa
Dogwood Therapeutics stock plummets after Phase 2b interim results - Investing.com
Dogwood Therapeutics reports positive interim phase 2b results in chemotherapy-induced neuropathic pain - marketscreener.com
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron - marketscreener.com
Dogwood reports positive interim results for pain treatment By Investing.com - Investing.com South Africa
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain - The Manila Times
Dogwood Therapeutics Announces Positive Interim Phase 2b - GlobeNewswire
Can Dogwood Therapeutics Inc. stock sustain institutional interestQuarterly Profit Report & Smart Swing Trading Alerts - ulpravda.ru
Why retail investors favor Dogwood Therapeutics Inc. stockJuly 2025 Big Picture & Safe Swing Trade Setups - Улправда
Published on: 2025-12-21 10:22:42 - moha.gov.vn
Finanzdaten der Dogwood Therapeutics Inc-Aktie (DWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):